|
1
|
Akira S and Takeda K: Toll-like receptor
signalling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curtin JF, Liu N, Candolfi M, Xiong W,
Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, et
al: HMGB1 mediates endogenous TLR2 activation and brain tumor
regression. PLoS Med. 6:e102009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goto Y, Arigami T, Kitago M, Nguyen SL,
Narita N, Ferrone S, Morton DL, Irie RF and Hoon DS: Activation of
Toll-like receptors 2, 3 and 4 on human melanoma cells induces
inflammatory factors. Mol Cancer Ther. 7:3642–3653. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ilvesaro JM, Merrell MA, Swain TM,
Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like
receptor-9 agonists stimulate prostate cancer invasion in vitro.
Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie W, Wang Y, Huang Y, Yang H, Wang J and
Hu Z: Toll-like receptor 2 mediates invasion via activating
NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res
Commun. 379:1027–1032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato Y, Goto Y, Narita N and Hoon DS:
Cancer cells expressing toll-like receptors and the tumor
microenvironment. Cancer Microenviron. 2(Suppl 1): S205–S214. 2009.
View Article : Google Scholar
|
|
7
|
Wolska A, Lech-Marańda E and Robak T:
Toll-like receptors and their role in carcinogenesis and anti-tumor
treatment. Cell Mol Biol Lett. 14:248–272. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rakoff-Nahoum S and Medzhitov R: Toll-like
receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: Report of incidence and mortality in China cancer
registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
|
|
12
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Killeen SD, Wang JH, Andrews EJ and
Redmond HP: Exploitation of the Toll-like receptor system in
cancer: A doubled-edged sword? Br J Cancer. 95:247–252. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmausser B, Andrulis M, Endrich S,
Müller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and
TLR9 on gastric carcinoma cells: An implication for interaction
with helicobacter pylori. Int J Med Microbiol. 295:179–185. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yi JY, Jung YJ, Choi SS, Hwang J and Chung
E: Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2
cells. Biochem Biophys Res Commun. 386:455–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cherfils-Vicini J, Platonova S, Gillard M,
Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F,
Dieu-Nosjean MC, Fridman WH, et al: Triggering of TLR7 and TLR8
expressed by human lung cancer cells induces cell survival and
chemoresistance. J Clin Invest. 120:1285–1297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheyhidin I, Nabi G, Hasim A, Zhang RP,
Ainiwaer J, Ma H and Wang H: Overexpression of TLR3, TLR4, TLR7 and
TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol.
17:3745–3751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eiró N, González L, González LO,
Andicoechea A, Fernández-Díaz M, Altadill A and Vizoso FJ: Study of
the expression of toll-like receptors in different histological
types of colorectal polyps and their relationship with colorectal
cancer. J Clin Immunol. 32:848–854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han JH, Park SY, Kim JB, Cho SD, Kim B,
Kim BY, Kang MJ, Kim DJ and Park JH and Park JH: TLR7 expression is
decreased during tumour progression in transgenic adenocarcinoma of
mouse prostate mice and its activation inhibits growth of prostate
cancer cells. Am J Reprod Immunol. 70:317–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin KJ, Lin TM, Wang CH, Liu HC, Lin YL
and Eng HL: Down-regulation of Toll-like receptor 7 expression in
hepatitis-virus-related human hepatocellular carcinoma. Hum Pathol.
44:534–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sligh JE Jr: New therapeutic options for
actinic keratosis and basal cell carcinoma. Semin Cutan Med Surg.
33(Suppl 4): S76–S80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu L and Chen S: Toll-like receptors
expressed in tumor cells: Targets for therapy. Cancer Immunol
Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelly MG, Alvero AB, Chen R, Silasi DA,
Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G: TLR-4
signaling promotes tumor growth and paclitaxel chemoresistance in
cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith MF Jr, Mitchell A, Li G, Ding S,
Fitzmaurice AM, Ryan K, Crowe S and Goldberg JB: Toll-like receptor
(TLR) 2 and TLR5, but not TLR4, are required for Helicobacter
pylori induced NF-kappa B activation and chemokine expression by
epithelial cells. J Biol Chem. 278:32552–32560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang SW, Liu KT, Chang CC, Chen YJ, Wu
CY, Tsai JJ, Lu WC, Wang YT, Liu CM and Shieh JJ: Imiquimod
simultaneously induces autophagy and apoptosis in human basal cell
carcinoma cells. Br J Dermatol. 163:310–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aspord C, Tramcourt L, Leloup C, Molens
JP, Leccia MT, Charles J and Plumas J: Imiquimod inhibits melanoma
development by promoting pDC cytotoxic functions and impeding tumor
vascularization. J Invest Dermatol. 134:2551–2561. 2014. View Article : Google Scholar : PubMed/NCBI
|
